🔬Deep Research
WGS — GeneDx Holdings Corp · catalysts, narrative & risks
GeneDx Holdings Corp. (WGS) — Research Snapshot as of 2026-10-31
Current Snapshot
GeneDx Holdings Corp. (Nasdaq: WGS) is a genomic diagnostics company providing whole exome/whole genome sequencing and AI-supported interpretation for rare disease, pediatric, hereditary, and cancer testing. It was formerly Sema4 (which acquired GeneDx from OPKO Health in 2022 and renamed itself). [5], [8], [18]
As of the last close on Friday, October 30, 2026, the stock traded at $69.06, down 2.76% on the day, with a market capitalization of $2.06 billion. [8], [10], [12] The stock has a beta of 1.97 and a 52-week range of $32.21–$170.87, indicating high volatility and a significant pullback from its highs. [8], [18]
Recent Catalysts (last ~1–3 months)
AI-assisted research from the K3vl4r desk — not personalized investment advice. More research →